Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million
REPL•Quarterly net loss narrows
Replimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 million a year earlier.
Cash position and financing
Cash, cash equivalents and short-term investments totaled USD 195.3 million at quarter-end; August equity issuance added USD 141 million in net proceeds.
FDA approval and launch plans
FDA granted accelerated approval to TUDRIQEV with nivolumab in advanced melanoma; U.S. launch expected within 60 days, and the IGNYTE-3 readout is targeted for 2030.
Expenses decline on lower research and administrative costs
R&D expense fell to USD 49.3 million from USD 57.8 million, on lower personnel and direct research costs across IGNYTE, ARTACUS, CERPASS.
Selling, general and administrative costs dropped to USD 19 million from , including of stock-based compensation.
